Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
2019 ◽
Vol 14
(1)
◽
pp. 15-21
2016 ◽
Vol 55
(3)
◽
pp. 179-184
◽